Company profile: Rosemont Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of oral liquid medicines for patients with swallowing difficulties, manufacturing and supplying 130+ formulations across therapeutic categories. Offers R&D for new low-excipient liquid medications, GMP and ICH Q10-compliant, regularly inspected manufacturing, international distribution to 27+ markets, and educational resources for healthcare professionals.
Products and services
- Liquid Medicines: Engineers a portfolio of over 130 oral-liquid medicines for swallowing difficulties, spanning anesthesia, cardiovascular, CNS, endocrine, gastrointestinal, infections, oncology/immunosuppression, musculoskeletal, nutrition/blood, and respiratory categories
- Manufacturing Solutions: Produces GMP- and ICH Q10-compliant manufacturing assemblies, with facilities regularly inspected by regulatory agencies, ensuring controlled production of liquid medications
- Partnerships & International: Delivers latest-technology-driven liquid medicine products to over 27 international markets, leveraging expertise in research, development, and manufacturing of liquid medications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Rosemont Pharmaceuticals
Retrophin
HQ: United States
Website
- Description: Provider of therapies and programs for rare diseases, including FILSPARI (sparsentan) for adults with IgA nephropathy; a late-stage therapy for focal segmental glomerulosclerosis; a potential disease-modifying therapy for classical homocystinuria; preclinical Alagille syndrome research with NIH and ALGSA; and support for newborn screening modernization and a telehealth model to improve specialist access.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Retrophin company profile →
Covagen
HQ: Switzerland
Website
- Description: Provider of bispecific FynomAbs by fusing human Fynomer binding proteins to antibodies, creating protein-based therapeutics with novel modes of action and enhanced efficacy for the treatment of inflammatory diseases and cancer; ability to fuse Fynomers to multiple antibody sites enables tailored architectures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Covagen company profile →
CorMedix
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products targeting cardiac, renal, and infectious diseases. Offers DefenCath, a catheter lock solution with taurolidine and heparin to reduce catheter-related bloodstream infections in adult patients with kidney failure on chronic hemodialysis via central venous catheter.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CorMedix company profile →
Roquefort Therapeutics
HQ: United Kingdom
Website
- Description: Provider of pre-clinical anti-cancer therapeutics, including Midkine-targeting antibodies; antisense oligonucleotides to reduce Midkine in cancer cells; gene-editing RNA and mRNA therapies for solid tumors; STAT-6 siRNA therapeutics; and MK cell therapy with direct and NK cell-mediated action, advancing candidates toward clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Roquefort Therapeutics company profile →
Stada
HQ: Germany
Website
- Description: Provider of pharmaceuticals and non-prescription consumer health products, operating on three pillars: OTC consumer healthcare, generics, and specialty pharmaceuticals. Sells products in over 120 countries, including acetaminophen, lactulose, Grippostad-C, Vitaprost, Cardiomagnyl, Xefocam Rapid, Aqualor, Edarbi, and Levomekol.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stada company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Rosemont Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Rosemont Pharmaceuticals
2.2 - Growth funds investing in similar companies to Rosemont Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Rosemont Pharmaceuticals
4.2 - Public trading comparable groups for Rosemont Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →